跳至主要内容
临床试验/ACTRN12618001179224
ACTRN12618001179224已完成未知

Safety and efficacy study of colchicine prophylaxis in gout patients commencing urate lowering therapy

niversity of Otago0 个研究点目标入组 200 人开始时间: 2018年7月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • *Gout according to the 2015 American College of Rheumatology and European League Against Rheumatism criteria
  • Serum urate >0.36mmol/
  • *At least one self-reported gout flare in last 6 months
  • *Fulfilling American College of Rheumatology criteria for urate lowering therapy with allopurinol (gout with greater than or equal to 2 flares in a year, tophi, chronic kidney disease greater than or equal to stage 2 (eGFR<90mls/min/1.73m2), or past kidney stones)
  • *Agreeable to starting allopurinol
  • *Ability to give informed consent
  • *Ability to communicate via telephone

排除标准

  • *Contra-indication or previous intolerance to allopurinol
  • *Contra-indication or previous intolerance to colchicine
  • *Urate lowering therapy within 1 month of enrolment
  • *Stage 4 or 5 chronic kidney disease
  • *Concomitant azathioprine, cyclosporine, or other immunosuppression
  • *Unstable co-morbid health conditions (e.g stage 4 heart failure, recent myocardial infarction, advanced cancer)
  • *Unable to comply with study procedures
  • *Use of regular non steroidal anti inflammatory for other medical conditions.

研究者

相似试验